Pilar Auñón

Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry

José López‐Sendón, Carlos Álvarez-Ortega, Pilar Auñón et al. · European Heart Journal · 2020 · 284 citations · Full text

Medicine, Cardiology, Oncology +17

Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry

Juan Caro‐Codón, Teresa López‐Fernández, Carlos Álvarez-Ortega et al. · European Journal of Preventive Cardiology · 2020 · 63 citations

Medicine, Cardiology, Oncology +17

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

Wolfgang Janni, Emilio Alba, Thomas Bachelot et al. · Breast Cancer Research and Treatment · 2018 · 51 citations

Medicine, Oncology, Pharmacology +17

[Nutritional risk evaluation and establishment of nutritional support in oncology patients according to the protocol of the Spanish Nutrition and Cancer Group].

M. M. Marín, C. Gómez Candela, R. Castillo Rabaneda et al. · PubMed · 2009 · 46 citations

Agriculture, Nutrition, Oncology +17

Thrombotic microangiopathy in patients with malignant hypertension

Teresa Cavero, Pilar Auñón, Fernando Caravaca‐Fontán et al. · Nephrology Dialysis Transplantation · 2022 · 43 citations

Medicine, Hematology, Nephrology +11